Document ID: chunk:federal_register_of_legislation:F2024C01027:reg:10:p41
Version: federal_register_of_legislation:F2024C01027
Segment Type: reg
Provision Reference: reg 10 (pt 41/63)
Character Range: 1659334–1663719

engage in any problematic use of substances (within the meaning given by section 1.1 of Annex 1, Personnel Licensing, to the Chicago Convention)
3.6                                                  If there is any personal history of problematic use of a substance (within the meaning given by section 1.1 of Annex 1, Personnel Licensing, to the Chicago Convention):
                                                     (a) the person's abstinence from problematic use of the substance is certified by an appropriate specialist medical practitioner; and
                                                     (b) the person is not suffering from any safety‑relevant sequelae resulting from the person's use of the substance; and
                                                     (c) the person provides evidence that the person is undertaking, or has successfully completed, an appropriate course of therapy
                                                     Note: In Annex 1, Personnel Licensing, to the Chicago Convention, 'Problematic use of substances' is defined as follows:
                                                      'The use of one or more psychoactive substances by aviation personnel in a way that:
                                                            a) constitutes a direct hazard to the user or endangers the lives, health or welfare of others; and/or
                                                            b) causes or worsens an occupational, social, mental or physical problem or disorder.'.
                                                      'Psychoactive substances' is there defined as 'Alcohol, opioids, cannabinoids, sedatives and hypnotics, cocaine, other psychostimulants, hallucinogens, and volatile solvents, whereas coffee and tobacco are excluded.'.
Nervous system
3.7                                                  Has no established medical history or clinical diagnosis of:
                                                     (a) a safety‑relevant disease of the nervous system; or
                                                     (b) epilepsy; or
                                                     (c) a disturbance of consciousness for which there is no satisfactory medical explanation and which may recur
3.8                                                  Is not suffering from safety‑relevant effects of a head injury or neurosurgical procedure
Cardiovascular system
3.9                                                  Has no safety‑relevant heart abnormality
3.10                                                 Systolic and diastolic blood pressures are within limits specified by CASA from time to time in the Designated Aviation Medical Examiner's Handbook (even if approved drugs are used to maintain the blood pressure within those limits)
3.11                                                 Has no significant functional or structural abnormality of the circulatory tree
Respiratory system
3.12                                                 Is not suffering from a safety‑relevant condition of the respiratory system
Alimentary system and metabolic disorders
3.13                                                 Is not suffering from a safety‑relevant defect of the digestive system or its adnexae, nor from any safety‑relevant effect of disease or trauma of, or an operation on, the digestive system or its adnexae
3.14                                                 Is not suffering from safety‑relevant metabolic, nutritional or endocrine disorders
3.15                                                 If suffering from diabetes mellitus:
                                                     (a) the condition is satisfactorily controlled without the use of any anti‑diabetic drug; or
                                                     (b) if an oral anti‑diabetic drug is used to control the condition:
                                                     (i) the condition is under on‑going medical supervision and control; and
                                                     (ii) the oral drug is approved by CASA
Reticulo‑endothelial system
3.16                                                 Is not suffering from a safety‑relevant condition of any of the following kinds:
                                                     (a) localised or generalised enlargement of the lymphatic